Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Penbutolol: a new beta-adrenergic blocking agent.

K D Schlanz1, R L Thomas

  • 1Division of Clinical and Hospital Pharmacy, College of Pharmacy, University of Cincinnati, OH 45267.

DICP : the Annals of Pharmacotherapy
|April 1, 1990
PubMed
Summary

Penbutolol is a potent, noncardioselective beta-blocker for hypertension treatment. It offers a 24-hour hypotensive effect with good tolerability, similar to other beta-blockers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IDF diabetes Atlas: A worldwide review of studies utilizing retinal photography to screen for diabetic retinopathy from 2017 to 2024 inclusive.

Diabetes research and clinical practice·2025
Same author

Trends in certifications of overall vision impairment and that due to diabetic retinopathy/maculopathy in England and Wales, 2009/2010 to 2019/2020: a retrospective database analysis.

BMJ open·2025
Same author

IDF Diabetes Atlas: A review of studies utilising retinal photography on the global prevalence of diabetes related retinopathy between 2015 and 2018.

Diabetes research and clinical practice·2019
Same author

Properties and Function of the Flexor Hallucis Capsularis Interphalangeus Tendon.

Clinical anatomy (New York, N.Y.)·2019
Same author

Acute shoulder injuries: A clinical review of diagnosis and management in the deployed Naval environment.

Journal of the Royal Naval Medical Service·2018
Same author

Cancer survivors' concealment or disclosure of diagnosis: Implications for return to work.

Work (Reading, Mass.)·2015

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Hypertension management requires effective and well-tolerated therapeutic agents.
  • Beta-adrenergic blocking drugs play a crucial role in cardiovascular therapy.

Purpose of the Study:

  • To review the pharmacological properties and clinical use of penbutolol for hypertension.
  • To assess the efficacy, pharmacokinetics, and safety profile of penbutolol.

Main Methods:

  • Review of existing literature on penbutolol's pharmacology and clinical trials.
  • Analysis of pharmacokinetic data including absorption, metabolism, and elimination.
  • Evaluation of clinical data regarding efficacy and adverse effects.

Main Results:

  • Penbutolol is a potent, noncardioselective beta-blocker with intrinsic sympathomimetic activity, approximately four times more potent than propranolol.
  • Rapid absorption after oral administration, extensive hepatic metabolism, and a long terminal half-life (17.6-26.5 hours) support once-daily dosing.
  • Effective 24-hour hypotensive effect achieved with initial doses of 20 mg/day, with optimal results at 20-40 mg/day. Adverse effects are comparable to other beta-blockers.

Conclusions:

  • Penbutolol is an effective and well-tolerated option for hypertension treatment.
  • Its pharmacokinetic profile supports a convenient once-daily dosing regimen.
  • Dosage adjustment is not typically required in renal insufficiency.

Related Experiment Videos